Table 1.
Clinical characteristics of patients with COVID-19
| Overall n = 49 | Moderate disease n = 24 (49%) | Severe disease n = 15 (31%) | Critical disease n = 10 (20%) | |
| Male, n (%) | 26 (53%) | 10 (42%) | 9 (60%) | 7 (70%) |
| Age (years) | 61 (49–74) | 53 (43–71) | 68 (48–78) | 66 (52–75) |
| Comorbidities | ||||
| Hypertension | 20 (41%) | 6 (25%) | 7 (47%) | 7 (70%) |
| Diabetes | 12 (24.5%) | 6 (25%) | 4 (27%) | 2 (20%) |
| Pneumopathy | 5 (10%) | 0 | 2 (13%) | 3 (30%) |
| Heart disease | 9 (18%) | 4 (17%) | 2 (13%) | 3 (30%) |
| Active malignancy | 1 (2%) | 0 | 1 (7%) | 0 |
| Other immunosuppression | 3 (6%) | 0 | 1 (7%) | 2 (20%) |
| Chronic kidney disease | 4 (8%) | 1 (4%) | 1 (7%) | 2 (20%) |
| CRP (mg/dL) | 5 (3–9) | 4 (2–6) | 6 (4–9) | 14 (4–24)∗ |
| Ferritin (ng/mL) | 558 (268–1,026) | 278 (180–632) | 636 (422–1,230)∗ | 988 (562–1,436)∗ |
| D-dimer (ng/mL) | 600 (400–1,150) | 500 (400–775) | 800 (500–1,800)∗ | 1,050 (400–4,050)∗ |
| Acute Kidney Injury | 2 (4%) | 0 | 0 | 2 (20%) |
| Immunomodulatory therapy | 22 (45%) | 6 (25%) | 6 (40%) | 10 (100%)∗,† |
| Hospital length of stay (days) | 9 (4–15) | 6 (3–14) | 9 (4–11) | 20 (12–33)∗,† |
| Days of symptoms | 7 (5–10) | 6,5 (4–9) | 7 (5–13) | 6,5 (5–9) |
| 28-day mortality | 1 (2%) | 0 | 0 | 1 (10%) |
Data are expressed as median (interquartile range) or absolute count (percentage).
∗
P < 0.05 compared with moderate disease group.
†
P < 0.05 compared with severe disease group.
CRP indicates C-reactive protein.